{"id":"W2776537462","doi":"10.1016/s1470-2045(17)30693-9","title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; Queen's University","funders":"Bayer Fund; Roche; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Novartis; Dietmar Hopp Stiftung; AbbVie; Merck; GlaxoSmithKline; Pfizer; Boehringer Ingelheim; Siemens USA; AstraZeneca; National Institutes of Health; Medtronic","keywords":"Medicine; Clinical trial; Systemic therapy; Oncology; Guideline; Internal medicine; Efficacy; Regimen; Surrogate endpoint; Clinical study design; Intensive care medicine; Drug; Cancer; Pharmacology; Pathology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.03187198,0.001014747,0.008178258,0.0003312512,0.0002909594,0.0001016573,0.00138224,0.0006662931,0.00006455137],"category_scores_gemma":[0.006484521,0.0005072248,0.0009020382,0.0003757867,0.0005174477,0.00008627196,0.0003436551,0.001875859,0.00001644489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001449847,"about_ca_system_score_gemma":0.002825397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002912276,"about_ca_topic_score_gemma":0.0004820604,"domain_scores_codex":[0.9621099,0.0312039,0.003503971,0.001372127,0.000619754,0.001190326],"domain_scores_gemma":[0.9514416,0.04298598,0.003110094,0.002086266,0.0001435885,0.0002324151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1689321,0.004361388,0.0007397596,0.0008110047,0.002835613,0.001295363,0.0001301246,0.00002827782,0.000001504006,0.00008301714,0.1180016,0.7027802],"study_design_scores_gemma":[0.1045316,0.01687272,0.0006205332,0.003887282,0.004693494,0.0001863402,0.00009562566,0.00006588942,2.575135e-7,0.00007124631,0.8685731,0.0004018969],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00945312,0.9170694,0.003716356,0.02932289,0.002240754,0.03503776,0.00297192,0.0001116727,0.00007611327],"genre_scores_gemma":[0.006902603,0.9112608,0.03280088,0.02076673,0.004526278,0.01417733,0.008769356,0.0005316654,0.0002643891],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7505715,"threshold_uncertainty_score":0.9997379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3621266698721051,"score_gpt":0.5249072376343089,"score_spread":0.1627805677622038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}